Background. Cost-effectiveness analysis (CEA) estimates can vary substantially across patient subgroups when patient characteristics influence preferences, outcome risks, treatment effectiveness, life expectancy, or associated costs. However, no systematic review has reported the frequency of subgroup analysis in CEA, what type of heterogeneity they address, and how often heterogeneity influences whether cost-effectiveness ratios exceed or fall below conventional thresholds. Methods. We reviewed the CEA literature cataloged in the Tufts Medical Center CEA Registry, a repository describing cost-utility analyses published through 2016. After randomly selecting 200 of 642 articles published in 2014, we ascertained whether each study reported subgroup results and collected data on the defining characteristics of these subgroups. We identified whether any of the CEA subgroup results crossed conventional cost-effectiveness benchmarks (e.g., $100,000 per QALY) and compared characteristics of studies with and without subgroup-specific findings. Results. Thirty-eight studies (19%) reported patient subgroup results. Articles reporting subgroup analyses were more likely to be US-based, government funded (v. drug industry-or nonprofit foundation-funded) studies, with a focus on primary or secondary (v. tertiary) prevention (P \ 0.05 for comparisons). One or more patient characteristics were used to stratify CEA results 68 times within the 38 studies, with most stratifications using one characteristic (n = 47), most commonly age (n = 35). Among the 23 stratifications reported alongside average ratios in US studies, 13 produced subgroup ratios that crossed a conventional CEA ratio benchmark. Conclusions. Most CEAs do not report any subgroup results, and those that do most often stratify only by patient age. Over half of the subgroup analyses reported could lead to different value-based decision making for at least some patients.
does exert some influence on public health and clinical practice guidelines in the US. 1 The cost-effectiveness of an intervention may depend on the characteristics of the individuals to whom it is targeted; i.e., whether the patients have co-morbid conditions or other observable characteristics that may influence their life expectancy, treatment or outcome preferences, individual outcome risks, intervention benefits and harms, or individual health care costs. However, many CEAs report incremental costs and benefits of an intervention across a range of individuals, on average, and without regard to specific and observable characteristics of individual patients.
Better characterization of how cost-effectiveness varies by observable patient characteristics could help to identify which patients should be targeted at the time of a treatment decision based on their characteristics. Such an approach could help mitigate wasteful or inefficient spending on patients for whom a treatment confers minimal value, even for treatments that are worthwhile on average. [2] [3] [4] Conversely, physicians could recommend interventions that confer high value for a subset of patients, even when evidence shows that the intervention is not worthwhile on average. Although studies now more than a decade old have highlighted the need for more stratified and personalized cost-effectiveness information, 5 no review has systematically elucidated the frequency with which this recommendation has been incorporated into CEAs and the implications for differential decision making.
This paper aimed to review the CEA literature to determine: 1) how often CEAs estimate cost-effectiveness variation by identifiable patient characteristics; 2) the characteristics of studies (i.e., country of study, disease area, funding source) that incorporate patient heterogeneity; and 3) how often patient subgroup results would lead to targeted recommendations that differ from recommendations based on average, according to conventional CE thresholds that reflect ''reasonable'' value for money.
Methods

Data
The Tufts Medical Center CEA Registry (www.cearegisty.org) 6 catalogs selected information from all Englishlanguage cost utility analyses (CUAs) published through 2016. 7 CUAs are CEAs that quantify health benefits in terms of quality adjusted life years (QALYs). We describe the CEA Registry search strategy and data collection methods elsewhere. 6 Briefly, Registry reviewers searched Medline for English-language articles using the keywords ''QALY'', ''quality-adjusted'' and ''cost-utility analysis.'' Researchers screened retrieved abstracts to identify studies reporting original cost-effectiveness estimates expressed using QALYs. The search excluded reviews, editorials and other methodological studies. Two independent reviewers screen selected papers in full to extract information on study methods, incremental cost-effectiveness ratios (ICERs) and health-state preference (i.e., ''utility'') weights. The CEA Registry catalogs more than 5,600 English-language CUAs and more than 14,400 cost-effectiveness ratios.
Review and Analysis
We used only the CUAs contained in the Registry for this study and relied on previously extracted study methods and results information. Because of the time it took to review articles and to extract additional data not already contained in the Registry, we randomly selected 200 CUAs from the 642 articles cataloged in the Tufts CEA Registry from 2014, the most recent year of data in the Registry when this study began. For each study in our review, we extracted data contained in the CEA Registry on the type of intervention being evaluated, disease classification, country of study, funding source, and prevention stage. Using pre-specified data collection forms, 2 trained readers reviewed each article to determine whether it reported cost-effectiveness results for subgroups characterized by one or more identifiable patient characteristics. Among those studies that reported results by patient subgroups, we collected additional data from each article, including quality metrics based on previously published theoretical and methodological guidance on incorporating patient heterogeneity into CEAs. 2, 8, 9 This information included whether the methods section of the paper specified the subgroup, whether each pre-specified patient subgroup had CEA results presented; the terms used by authors to identify heterogeneity (i.e., subgroup, stratification or sensitivity analysis); whether the reported costs, QALYs, and ICERs included estimates of statistical uncertainty; whether the authors discussed different interpretations of the value of the intervention for different patient subgroups; and whether the authors discussed any concerns about distributional equity related to heterogeneity.
We collected information on the observable clinical and socio-demographic characteristics that defined the patient subgroups (age, gender, race, severity of disease, presence of disease/comorbid conditions, lifestyle factors), and whether the study used these variables alone (univariate) or in combination (multivariate) to define subgroups. We also identified studies that stratified results based on patient characteristic-predicted risk variables. In papers we reviewed, these risk predictions included both previously developed scores, such as the Framingham risk score, 10 and unique risk algorithms developed based on observable or measurable patient characteristics.
Differences in identifiable clinical and sociodemographic patient characteristics can lead to variability in at least 5 key CEA inputs ( Figure 1 ): 1) life expectancy; 2) baseline risk of health outcomes; 3) treatment effect; 4) patient preferences for treatment or outcomes; and 5) costs, including intervention costs, costs of future clinical events, and productivity costs. 2 Patient subgroups within CEAs conducted alongside randomized controlled trials (RCTs) inherently capture differences across all domains but may not measure or report all of these differences. Subgroups created within model-based CEAs would ideally be created to account for differences in model inputs for each subgroup along all domains, but the feasibility of such an approach would be dependent on the exactness of the model. We examined what potential sources of heterogeneity were accounted for in the subgroup analyses in our review, based on what was reported in the paper.
In the subset of reviewed studies that were conducted in the US, we compared subgroup ratios reported alongside average ratios to identify situations in which subgroup results would cross conventional CEA ratio US benchmarks and could lead to different value-based decision making for certain patients. Specifically, we identified cases in which the stratification created a subgroup ratio that was more favorable than the average CEA result at a variety of thresholds: cost-saving (at least one subgroup is cost-saving, average is not); $50,000/QALY (at least one subgroup \$50,000/QALY, average is .$50,000/QALY); $100,000/QALY (at least one subgroup \$100,000/QALY, average is .$100,000/QALY); and dominated (at least one subgroup is not dominated but the population average is). We also identified cases in which the stratification created a subgroup ICER that was less favorable than the average CEA result at the same thresholds (e.g., cost-saving [average is cost-saving, at least one subgroup is not], $50,000/QALY [average \$50,000/QALY, at least one subgroup is .$50,000/ QALY], and so forth). We adjusted all ICERs to 2015 US dollars using the Bureau of Labor Statistics 2015 Consumer Price Index Report.
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Following data collection, readers met with a third reviewer to resolve any discrepancies in data coding. We summarized the review data with descriptive statistics. Using chi-squared tests to determine statistical significance, we compared Registry data from studies that did and did not include subgroups.
Results
According to our categorization, 38 of the 200 reviewed studies (19%) reported subgroup results based on observable or measurable patient information. Articles that incorporated patient heterogeneity were more likely to be US-based studies, to include a government funder, and to focus on primary or secondary (v. tertiary) prevention (P \ 0.05 for all comparisons; Table 1 ).
We found that one or more patient characteristics were used to stratify the results 68 times within the 38 studies with subgroups ( Table 2 ). The most common stratifying variable was patient age (35 stratifications), followed by a clinical (lab, test or procedure) result (n = 7) and predicted risk (n = 6). Most of the stratifications examined only one patient characteristic (n = 47), Figure 1 How patient variability can be assessed in cost-effectiveness analyses. whereas 15 stratifications used 2 or more characteristics to define subgroups, and 6 used a predicted risk score.
Although we expected patient subgroups to differ on at least 5 sources of variability (life expectancy, baseline risk, treatment effect, preferences, and cost), as outlined above, few studies described how patient subgroups differed on more than one of these factors (Table 2) , and no studies mentioned any sources of heterogeneity extending beyond these 5 pre-specified factors. For 35 stratifications, the authors reported differentiating subgroups based on one source of heterogeneity, with differing baseline risks (n = 16) being the most common. Among the 68 stratifications we identified, only in 17 did the authors report more than one source of subgroup variability. For 16 stratifications, there was no mention of the sources of variability differentiating the subgroups (Table 2) .
When examining subgroup results from 23 stratifications that were reported alongside average ratios in 17 US-based studies, we found 13 cases in which the stratification produced at least one ratio that crossed conventional US CEA ratio benchmarks as compared with the population average ratio. This means that, for a particular intervention, over half the cases had at least some group of patients that should be receiving different treatment recommendations from the average patient, based on the value of the intervention. Specifically, the results from 8 stratifications created at least one subgroup ratio that was more favorable than the average CEA result, most frequently at the $50,000/QALY threshold ( Table  3) . The results from 10 stratifications created at least one subgroup ratio that was less favorable than the average CEA result, most frequently at the $100,000/QALY threshold. In 10 stratifications, subgroup ratios produced were all on the same side of conventional CEA ratio benchmarks as the average ratios (Table 3) , and would not lead to different value-based decisions for subgroup patients compared with the overall group. Most of the papers with subgroups (n = 32) prespecified in the methods section that they would report the results according to all of the patient characteristics ultimately used for stratification (Table 4) ; although, the specific terms ''subgroup'' or ''stratified'' analysis was only mentioned in 9 of these papers. In the remaining papers, the authors labeled the stratified analyses as ''sensitivity'' or ''scenario'' analyses (n = 15) or did not use a term (n = 14). All studies reported the CEA results separately for each pre-specified subgroup but only 9 included some type of uncertainty estimate around the subgroup results, either in the cost component of the CEA, the QALY, or both. Authors discussed different interpretations of the value of the intervention for different subgroups in 15 papers; no papers discussed equity concerns related to the reporting of subgroup results.
Discussion
Over the past decade, the CEA literature has grown rapidly, 12 thereby warranting greater attention to the methods used, including how patient heterogeneity is assessed and reported. Incorporating patient heterogeneity into CEAs and using targeted value information as part of the clinical decision making process might lead to substantial gains in efficiency, because interventions that are cost effective overall may be cost-ineffective in many patients to which they are applied. Our review indicates that most CEAs do not stratify results by observable patient characteristics, indicating that we currently do not have all the information we need to routinely target interventions to certain individuals and groups based on value. Among US studies that did report heterogeneity, we found that over half of the reported subgroup results would potentially lead to different value-based decision making for at least some patients as compared with the average patient.
The lack of subgroup consideration in CEAs is problematic because population-level evidence is frequently insufficient to guide informed decision making at the individual level. For example, previous studies have shown that patients enrolled in RCTs often have large variation in baseline risk; this can have a substantial impact on the absolute treatment effects, 13 which could lead to very different cost-effectiveness estimates or even harm exceeding benefit. In CEAs, the relevant patient variability that may influence CEA results extends beyond baseline risk to include life expectancy, treatment effect, patient preferences, and costs, all of which should define patient variability in subgroups. Among studies in our review that did include subgroups, most authors reported accounting for only one source of Stratification creates a ratio that was more favorable than the average CEA ratio at: heterogeneity, most frequently baseline risk. Although this under-accounting of the sources of heterogeneity in analyses has the potential to bias the subgroup results, 14 it is hard to infer the direction of this bias, because the different components of heterogeneity may operate in compensatory directions or synergistically.
The absence of patient subgroups in CEAs is not surprising, and likely reflects limitations in the primary literature and data upon which analyses are based. Limitations in the reporting of subgroup analyses in clinical trials has been repeatedly noted; there are serious concerns about the credibility of subgroup analysis, and many fundamental issues about the best way to conduct these analyses remain controversial and unsettled. 15, 16 Some clinical trials may be underpowered to detect differences in treatment effect within subgroups, particularly for rare diseases or for illnesses with small patient populations, such as children. Even when subgroups are conducted within RCTs, the results of these subgroup analyses are often not presented in sufficient detail to adequately create fully defined subgroup analyses in model-based CEAs.
Furthermore, attempts to balance the efficient use of resources with concerns for distributional equity have led to guidance in countries such as the UK that highlight the legal obligations of decision makers to avoid health resource prioritization that would discriminate against individuals based on age, gender, disability, race/ethnicity, and other socio-demographic characteristics. 17 We find that studies incorporating patient heterogeneity are more likely to originate from the US. This may reflect the less stringent regulatory concerns and restrictions regarding distributional equity in the US compared to other countries. Notably, the Second Panel on Costeffectiveness in Health and Medicine notes the ethical concerns in conducting CEAs targeted at certain groups of individuals, and recommends providing decision makers with sufficient information regarding equity issues alongside cost-effectiveness results, 1 which can be used to infer the appropriateness of targeting specific subgroups in clinical and reimbursement policies.
We found that the vast majority of CEA subgroups were created using only one observable patient variable. Previous research 18 has highlighted several fundamental problems with the use of univariate subgroups in clinical research, and these concerns are relevant for costeffectiveness research. Specifically, because each patient has innumerable characteristics, using univariate (onevariable-at-time) subgroups disaggregates results into a series of groups that are not mutually exclusive, such that one patient will fall into many different subgroups, each with potentially different results, motivating potentially different decisions. 19 One-variable-at-a-time subgroup analyses may therefore fail to capture the substantial heterogeneity across individual patients, because they compare groups of patients that differ systematically only on a single characteristic (i.e. gender) even though patients differ simultaneously across many characteristics (gender, race, history of disease, etc.). These limitations may be overcome in part by using multivariable subgroups and predicted risk models to define more patient-centric subgroups; 20 albeit, these were used infrequently in the papers we reviewed.
Properly characterizing heterogeneity in CEAs can help decision makers more efficiently target therapies and programs to certain individuals and groups rather than others because of low value. Ongoing efforts to curb low-value care, such as the ''Choosing Wisely'' campaigns in the US and Canada, have sought to limit the use of ''unnecessary'' health services by creating and disseminating lists of tests, treatments and procedures that generally provide little to no benefit to certain individuals, such as cardiac screening for low-risk, asymptomatic patients and pap smears for women under the age of 21. 21 This work has been further refined and developed into claims based measures of low-value care, used by researchers to characterize and quantify the overuse of health care resources in the US. [22] [23] [24] While important initiatives, these efforts generally define ''low-value'' care as care which provides little to no benefit, or has the potential for net harm in particular patient groups. The measures generally do not include information about services that should be avoided in subgroups of patients because the high costs of care outweigh the benefits. An expansion of work in this direction could lead to significant improvements in the efficiency of our health care system, but the results of our research show that the evidence generated from economic evaluations may not currently be sufficient to support such efforts. We did find that studies funded by a government source were more likely to include patient subgroups as compared to studies funded by private sources.
Guidance for researchers on when and how to incorporate heterogeneity into CEAs has previously been published. 2, 8, 9 These guidelines indicate that heterogeneity should be considered in the study design, analysis, and reporting phases of the study. In the design phase, researchers should identify the observable patient characteristics to be used in subgroups, the sources of heterogeneity that will be incorporated, and justify planned subgroup analyses, noting equity considerations. In the analysis and reporting phases, analysts are urged to separately report point estimates, statistical precision for each subgroup result, discuss whether subgroup differences lead to different conclusions, cite implications for equity, and explore the feasibility of subgroup targeting for clinical and reimbursement policy. We used these guidelines to evaluate the quality of the papers included in our review, and noted that studies fell short on several domains. Specifically, published CEAs rarely reported the statistical precision of subgroup CEA results, rarely discussed the different interpretations of the results for subgroups versus the average, and never discussed equity. Of note, we were not able to ascertain what information authors had pre-specified for their study and, instead, evaluated what information was stated in their methods sections. Regardless, the shortcomings noted in the available data shed some light on the work needed to improve the quality of this important component of CEAs.
Despite recommendations to report patient variability in CEAs, we find that few papers follow this advice, and those that do may lack the rigorous quality that would yield valid and credible results. Specifically, most patient subgroup analyses report one-variable-attime stratifications rather than examining the combined effects of multiple influential characteristics simultaneously, as recommended. 13, 20 Furthermore, these analyses do not account for the multiple ways in which patients may differ from each other in the analysis. Nevertheless, among reported subgroup analyses, over half produce results that would lead to different valuebased decision making for at least some patients. Thus, the full potential for subgroup analyses to inform value-based decisions remains largely unexplored. Improving the quality and utilization of subgroups in CEAs should be a focus of future research, as it may help decision makers target health care resources more efficiently.
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